Страна: Канада
мова: англійська
Джерело: Health Canada
TENOFOVIR DISOPROXIL FUMARATE; EMTRICITABINE
JAMP PHARMA CORPORATION
J05AR03
TENOFOVIR DISOPROXIL AND EMTRICITABINE
300MG; 200MG
TABLET
TENOFOVIR DISOPROXIL FUMARATE 300MG; EMTRICITABINE 200MG
ORAL
15G/50G
Prescription
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0251568001; AHFS:
APPROVED
2019-05-21
JAMP Emtricitabine / Tenofovir Disoproxil Fumarate (Emtricitabine and Tenofovir Tablets) Page 1 of 67 PRODUCT MONOGRAPH Pr JAMP Emtricitabine / Tenofovir Disoproxil Fumarate Emtricitabine and Tenofovir Tablets 200 mg / 300 mg (Emtricitabine / Tenofovir disoproxil fumarate) House Standard Antiretroviral Agent JAMP Pharma Corporation 1310 rue Nobel, Boucherville, Québec J4B 5H3, Canada Submission Control No.: 248455 Date of Revision: May 19, 2021 JAMP Emtricitabine / Tenofovir Disoproxil Fumarate (Emtricitabine and Tenofovir Tablets) Page 2 of 67 TABLE OF CONTENTS PART I. HEALTH PROFESSIONAL INFORMATION ............................................................................................. 3 SUMMARY PRODUCT INFORMATION ........................................................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................................................. 3 CONTRAINDICATIONS ....................................................................................................................................... 5 WARNINGS AND PRECAUTIONS ..................................................................................................................... 5 ADVERSE REACTIONS...................................................................................................................................... 14 DRUG INTERACTIONS ...................................................................................................................................... 22 DOSAGE AND ADMINISTRATION ................................................................................................................. 34 OVERDOSAGE ..................................................................................................................................................... 36 ACTION AND CLINICAL PHARMACOLOGY................................................................................................ 37 STORAGE Прочитайте повний документ